Home › Idiopathic Thrombocytopenic Purpura
Pag-aaral pangklinika para sa Idiopathic Thrombocytopenic Purpura na nagre-recruit sa U.S.
17 pag-aaral para sa Idiopathic Thrombocytopenic Purpura ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Los Angeles, CA7 pag-aaral
- Washington, DC6 pag-aaral
- Boston, MA6 pag-aaral
- Greenville, NC6 pag-aaral
- The Bronx, NY5 pag-aaral
- Durham, NC4 pag-aaral
- Rochester, MN4 pag-aaral
- Seattle, WA4 pag-aaral
- Portland, OR4 pag-aaral
- Houston, TX4 pag-aaral
- New Haven, CT3 pag-aaral
- Cedar Rapids, IA3 pag-aaral
- Cleveland, OH3 pag-aaral
- New Orleans, LA3 pag-aaral
- Kansas City, MO3 pag-aaral
- Philadelphia, PA3 pag-aaral
Ayos sa estado
- Arkansas3 pag-aaral
- California10 pag-aaral
- Connecticut3 pag-aaral
- District of Columbia6 pag-aaral
- Florida3 pag-aaral
- Illinois4 pag-aaral
- Iowa3 pag-aaral
- Louisiana4 pag-aaral
- Massachusetts6 pag-aaral
- Michigan3 pag-aaral
- Minnesota5 pag-aaral
- Missouri3 pag-aaral
- New Jersey4 pag-aaral
- New York7 pag-aaral
- North Carolina7 pag-aaral
- Ohio3 pag-aaral
- Oregon4 pag-aaral
- Pennsylvania3 pag-aaral
- Texas4 pag-aaral
- Virginia4 pag-aaral
- Washington4 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07421167A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07786077A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06721013Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07549698A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06722235A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
Nagre-recruitPhase 3
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07700238Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Set 14, 2026 · NCT07095127Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT07104565A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Nagre-recruitPhase 3
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT07059000A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06948318OM336 in Autoimmune Cytopenias
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT07083960Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Nagre-recruitPhase 1
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT06371417Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT07007962Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
Nagre-recruitPhase 2
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update May 12, 2026 · NCT05070845A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update May 1, 2026 · NCT06544499Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
Nagre-recruitPhase 1
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT04323748Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 10, 2025 · NCT06817395Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.